Treatment with lithium carbonate does not improve disease progression in two different strains of SOD1 mutant mice

Abstract

It has been shown that chronic treatment with lithium carbonate (Li(2)CO(3)) in presymptomatic SOD1G93A transgenic male mice, a model of ALS, was able to remarkably increase their lifespan through the activation of autophagy and the promotion of mitochondriogenesis and neurogenesis. This prompted us to test the lithium effect also in female SOD1G93A mice with two phenotypes of different disease severity. Female SOD1G93A mice of C57BL/6J or 129S2/Sv genetic background were treated daily with Li(2)CO(3) 37 mg/kg (1 mEq/kg) i.p. starting from age 75 days until death. Grip strength, latency to fall on rotarod and body weight were monitored twice weekly. At the time of death the spinal cord was removed to assess the number of motor neurons and to measure the expression of a marker of autophagy (LCII) and the activity of mitochondrial complex IV. We observed a significant anticipation of the onset and reduced survival in 129Sv/G93A and no effect in C57/G93A mice treated with lithium compared to vehicle treated mice. Moreover, lithium neither exerted neuroprotective effects nor increased the expression of LCII and the activity of mitochondrial complex IV in the spinal cord. The present study does not identify any therapeutic or neuroprotective effect of lithium in SOD1G93A female mice.

Preclinical research: Make mouse studies work

“…Concurrently, other groups attempted to reproduce the preclinical data and could not 12,13 . Although it is difficult to determine why the first study showed such a dramatic effect, its initial results are curious.…”

Guidelines for preclinical animal research in ALS/MND: A consensus meeting

“…Most researchers strongly suspect that the lack of success, including translational efficacy, of preclinical studies in ALS/MND is due to the use of one single rodent model, the transgenic SOD model carrying a high number of G93A mutations (16). Although its use remains justified as results are rapidly achieved, there are some major concerns:…”

Therapeutic Potential of Mood Stabilizers Lithium and Valproic Acid: Beyond Bipolar Disorder

“…Because defective autophagy has been found in diseased motor neurons (Venkatachalam et al, 2008), the autophagy-inducing properties of lithium are also believed to contribute to its protective effects in ALS (Fornai et al, 2008;Fulceri et al, 2011). However, one recent study in a female mouse ALS model found that lithium had no beneficial or neuroprotective effects (Pizzasegola et al, 2009). Although differences in sex and the genetic background of the mice cannot be excluded, the remarkably low serum steady-state lithium level (0.05-0.07 mM) found in these female mice from the latter study may account for this discrepancy.…”